- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 2339KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 819KB)
Tucatinib – March 2021
Tucatinib: Tablet 150 mg, Tablet 50 mg; Tukysa®
Last updated
16 July 2021